Literature DB >> 1531803

A rapid and simple method for the purification of tumor cells from ascitic fluid of ovarian carcinoma.

H W Hirte1, D A Clark, J Mazurka, G O'Connell, J Rusthoven.   

Abstract

Rapid isolation of tumor cells growing in clumps from the ascitic fluid of patients with ovarian carcinoma was achieved by harvesting cells from ascitic fluid and subsequently passing them over a 30-microns nylon mesh filter. Single cells and small cell aggregates passed through the mesh, and large cell clumps that had not passed through the filter were isolated by backwashing. Morphologically, the cells in the clumps consisted almost entirely of tumor cells. The clumps were analyzed by immunocytochemistry and only a small proportion of cells (3.1 +/- 0.5% to 8.3 +/- 0.8%) stained with anti-CD45 monoclonal antibody (a panleukocyte marker for cells of hematopoietic origin). Most of the cells in clumps stained positively (90.6 +/- 1.7% to 97.5 +/- 0.5%) with 2G3 (a monoclonal antibody binding to a high-molecular-weight carcinoma-associated antigen). Unfiltered cell populations, however, contained up to 34.4 +/- 2.1% contaminating CD45+ non-tumor cells. This method should be useful for rapidly and easily obtained highly enriched fresh ovarian carcinoma cells from ascitic fluid in a form in which they grow naturally.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1531803     DOI: 10.1016/0090-8258(92)90046-l

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  8 in total

1.  Telomerase activity in human ovarian carcinoma.

Authors:  C M Counter; H W Hirte; S Bacchetti; C B Harley
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-12       Impact factor: 11.205

2.  The use of ovarian cancer cells from patients undergoing surgery to generate primary cultures capable of undergoing functional analysis.

Authors:  Rachel L O Donnell; Aiste McCormick; Asima Mukhopadhyay; Laura C Woodhouse; Madeleine Moat; Anna Grundy; Michelle Dixon; Angelika Kaufman; San Soohoo; Ahmed Elattar; Nicola J Curtin; Richard J Edmondson
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

Review 3.  Modeling platinum sensitive and resistant high-grade serous ovarian cancer: development and applications of experimental systems.

Authors:  Paula Cunnea; Euan A Stronach
Journal:  Front Oncol       Date:  2014-04-17       Impact factor: 6.244

4.  Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancer.

Authors:  Tao Dao; Martin G Klatt; Tatyana Korontsvit; Sung Soo Mun; Sean Guzman; Marissa Mattar; Oliver Zivanovic; Chrisann K Kyi; Nicholas D Socci; Roisin E O'Cearbhaill; David A Scheinberg
Journal:  Cancer Immunol Immunother       Date:  2020-10-29       Impact factor: 6.968

5.  Establishment, characterization and downstream application of primary ovarian cancer cells derived from solid tumors.

Authors:  Thanasak Sueblinvong; Rahel Ghebre; Yoshie Iizuka; Stefan E Pambuccian; Rachel Isaksson Vogel; Amy P N Skubitz; Martina Bazzaro
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

6.  Primary culture and mRNA analysis of human ovarian cells.

Authors:  Lesley D. Dunfield; Trevor G. Shepherd; Mark W. Nachtigal
Journal:  Biol Proced Online       Date:  2002-10-28       Impact factor: 3.244

7.  Effective recovery of highly purified CD326(+) tumor cells from lavage fluid of patients treated with a novel cell-free and concentrated ascites reinfusion therapy (KM-CART).

Authors:  Yukino Kimura; Yui Harada; Noriko Yasuda; Takefumi Ishidao; Seiichi Yusa; Keisuke Matsusaki; Yoshikazu Yonemitsu
Journal:  Springerplus       Date:  2015-12-17

8.  WNT signaling inducing activity in ascites predicts poor outcome in ovarian cancer.

Authors:  Anna Kotrbová; Petra Ovesná; Tomáš Gybel'; Tomasz Radaszkiewicz; Markéta Bednaříková; Jitka Hausnerová; Eva Jandáková; Luboš Minář; Igor Crha; Vít Weinberger; Luděk Záveský; Vítězslav Bryja; Vendula Pospíchalová
Journal:  Theranostics       Date:  2020-01-01       Impact factor: 11.556

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.